Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.52 |
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.51 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.46 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 2/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | NMT2 | O60551 | 1/20 | 0.41 |
| ▸ | NMT1 | P30419 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13496274 | 0.97 | ERAP2 (0.54) | ERAP2LNPEPERAP1DPP8DPP9 | |
| SCHEMBL14560933 | 0.90 | GNAI3 (0.60) | ERAP2LNPEPERAP1DPP7GNAI3 | |
| SCHEMBL14560924 | 0.90 | GNAI3 (0.60) | ERAP2LNPEPERAP1DPP7GNAI3 | |
| SCHEMBL2734071 | 0.88 | ERAP2 (0.49) | ERAP2LNPEPERAP1DPP8DPP9 | |
| SCHEMBL13561938 | 0.87 | ERAP2 (0.47) | ERAP2LNPEPERAP1DPP8DPP9 | |
| SCHEMBL463738 | 0.87 | ERAP2 (0.47) | ERAP2LNPEPERAP1DPP8DPP9 | |
| SCHEMBL24198900 | 0.87 | FOLH1 (0.51) | ERAP2LNPEPERAP1DPP8DPP9 | |
| SCHEMBL21454270 | 0.87 | FOLH1 (0.51) | ERAP2LNPEPERAP1DPP8DPP9 | |
| SCHEMBL27182532 | 0.85 | ERAP2 (0.47) | ERAP2LNPEPERAP1DPP8DPP9 | |
| SCHEMBL13496278 | 0.85 | NMT1 (0.47) | ERAP2LNPEPERAP1SSTR3SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088757-B2 | Betulinol derivatives as anti-cancer agents | BIORINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088757-B2 | Betulinol derivatives as anti-cancer agents | BIORINGS LLC (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | SAXENA RESEARCH, LLC | 2009-07-09 | — | — | US | disclosed |
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | SAXENA RESEARCH, LLC | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176753-A1 | Betulinol derivatives as anti-cancer agents | BET1, BRDT, BRCA1 | ERAP2 4039/4885LNPEP 3532/4885ERAP1 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.